Journal club: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

from Thorax Podcast · host BMJ Group

Only one treatment is licensed for idiopathic pulmonary fibrosis and this only in Europe. Luca Richeldi (Center for Rare Lung Diseases, University of Modena, Italy) describes his phase 2 trial of a tyrosine kinase inhibitor to see if it could be safely and effectively used in patients with the disease. Dr Richeldi’s research was published in the New England Journal of Medicine. See also: http://www.nejm.org/doi/full/10.1056/NEJMoa1103690

Episode metadata supplied by the publisher feed · Published Feb 13, 2013

Embed this episode

Attribution link and audio player

Ready to play

Journal club: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

0:00 6:39

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Thorax Podcast?

This episode is 6 minutes long.

When was this Thorax Podcast episode published?

This episode was published on February 13, 2013.

Can I download this Thorax Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!